Newsletter Signup | Community
Treatment of Stage IV Rectal Cancer
Treatment of Stages I - III of Rectal Cancer
FDA Approves Checkpoint Inhibitor Targeted Immunotherapy for Treatment of Colorectal Cancer.
Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Colo-rectal Cancer
Approximately 10-15% of patients with colorectal cancer require a colostomy.
Targeting BRAF and EGFR Doubles Progression-free Survival in Metastatic Colorectal Cancer.